Pharmaceutical Bial Portela, Portugal’s largest drugmaker, has released positive results for a pivotal Phase III non-inferiority study comparing the efficacy and safety of eslicarbazepine acetate (ESL; trade name Zebinix) to controlled release carbamazepine (CBZ-CR) as monotherapy in newly-diagnosed adult patients with partial-onset seizures (POS). 7 December 2015